Recent research by Gao et al. published in Cell proposes that circulating β2-microglobulin impairs synaptic function through antagonizing NMDA receptors in two mouse models of Down syndrome (DS), providing a potentially novel therapeutic target to combat cognitive deficits in the early stage of DS.1 Here, HLA-G is linked to Dravet syndrome.